Tag: report

In its Q2 2025 update, the analyst lowers the global economic growth forecast to 2.34%, citing tariffs, trade policy uncertainties, and geopolitical tensions. Inflation is set to decrease globally but rise in the Americas and APAC. Central banks, including the ECB, are cutting rates. Business sentiments are down due to US tariffs. G20 trade shows growth, driven by US import hikes.

Global ammonia capacity is projected to increase by over 25% from 2025 to 2030, with North America leading due to high fertilizer demand. The versatile petrochemical's applications span agriculture, cleaning, and more. Explore global outlook, key projects, and investment opportunities in ammonia production.

The Australian legal cannabis market, valued at USD 123.9M in 2024, is projected to reach USD 540.6M by 2030, with a CAGR of 23.70%. Growth drivers include cannabis legalization, government initiatives, and new product launches. Market highlights: hemp dominates revenue, CBD leads the market, and industrial applications prevail. Explore comprehensive market insights, trends, and competitive strategies for informed decisions.

Explore the latest insights into the global construction industry with our comprehensive report. Discover market size, growth forecasts to 2029, and a breakdown of residential and non-residential segments. Analyze competitive pressures and key financials of top players, underpinning informed business strategies.

The global adrenal crisis market is witnessing significant growth driven by increasing adrenal insufficiency recognition and rising adrenal crisis incidents. The expanding global prevalence of autoimmune diseases and corticosteroid use for chronic conditions further accelerates market demand. However, challenges such as high treatment costs, limited awareness in low-income regions, and diagnostic complexities may slow adoption in emerging markets. Between 2025-2035, advancements in diagnostic technologies and innovative therapies are expected to bolster market growth, though access issues remain crucial. Key players like Eton Pharmaceuticals, Antares Pharma, and Pfizer are leading with product innovation and strategic partnerships.

– Absence of neurotoxicity of any grade in low-volume disease to-date –

MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone^® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 31,500,000 of its common shares (the “Shares”), accompanying Series A common warrants (the “Series A Common Warrants”) to purchase an aggregate of 31,500,000 common shares and accompanying Series B common warrants (the “Series B Common Warrants”) to purchase an aggregate of 31,500,000 common shares , at a combined public offering price of $1.50 per share and accompanying Series A Common Warrant and Series B Common Warrant and (ii) in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase 3,502,335 common shares, accompanying Series A Common Warrants to purchase an aggregate of 3,502,335 common shares and accompanying Series B Common Warrants to purchase an aggregate of 3,502,335 common shares, at a combined public offering price of $1.499 per pre-funded warrant and accompanying Series A Common Warrant and Series B Common Warrant, which represents the combined public offering price for the Shares and accompanying common warrants less the $0.001 per share exercise price for each such pre-funded warrant. The proceeds to Milestone from the Offering, before deducting underwriting commissions and offering expenses payable by Milestone, are expected to be approximately $52.5 million. The Offering is expected to close on or about July 14, 2025, subject to satisfaction of customary closing conditions.

Discover the definitive U.S. Cereal Manufacturing Industry analysis with projections reaching $17.97 billion by 2031. Access historical data, revenue forecasts, and key benchmarks. Ideal for financial analysts, M&A advisors, and consultants. Includes metrics for top companies like General Mills and Kellogg.